Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1986 May;29(5):887–893. doi: 10.1128/aac.29.5.887

Cefotetan pharmacokinetics in volunteers with various degrees of renal function.

B R Smith, J L LeFrock, P T Thyrum, B A Doret, C Yeh, G Onesti, A Schwartz, J J Zimmerman
PMCID: PMC284173  PMID: 3460524

Abstract

Twenty-six volunteers with various degrees of renal function were given a single 1-g dose of cefotetan intravenously over 30 min. Concentrations of cefotetan and cefotetan tautomer in plasma and urine were determined by high-performance liquid chromatography. The pharmacokinetic parameters for cefotetan were calculated according to a two-compartment open model. The mean plasma cefotetan concentration at the end of the intravenous infusion did not vary with renal function and ranged between 122 and 126 micrograms/ml. The mean terminal half-life was 4.2 h in normal volunteers and 9.9 h in volunteers with moderate renal impairment. There was a significant linear correlation between the systemic clearance of cefotetan and creatinine clearance. The cumulative amount of cefotetan excreted in the urine over 24 h in normal volunteers was approximately 49% of the dose, but this was reduced in volunteers with moderate renal impairment. The mean urinary cefotetan concentrations generally peaked during the 2- to 4-h interval after dosing. Cefotetan tautomer was sporadically detected in the plasma and urine of approximately 50% of the volunteers. The mean plasma cefotetan tautomer concentrations and mean total cumulative urinary recoveries of cefotetan tautomer were only minimal compared with those for cefotetan. The mean percentage of the dose excreted in the urine as cefotetan tautomer was not significantly affected by the degree of renal impairment. Recommendations for the dosing of cefotetan in renal-impaired patients are given.

Full text

PDF
887

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adam H. K., Houghton H. L., Yates R. A., Young J., Donnelly R. J. Pharmacokinetics and tolerance of a 24-h infusion of cefotetan disodium (with and without loading dose) in normal Caucasian volunteers. J Antimicrob Chemother. 1983 Jan;11 (Suppl):193–199. doi: 10.1093/jac/11.suppl_a.193. [DOI] [PubMed] [Google Scholar]
  2. Ayers L. W., Jones R. N., Barry A. L., Thornsberry C., Fuchs P. C., Gavan T. L., Gerlach E. H., Sommers H. M. Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing. Antimicrob Agents Chemother. 1982 Nov;22(5):859–877. doi: 10.1128/aac.22.5.859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  4. Dettli L. Drug dosage in renal disease. Clin Pharmacokinet. 1976;1(2):126–134. doi: 10.2165/00003088-197601020-00004. [DOI] [PubMed] [Google Scholar]
  5. Guibert J., Kitzis M. D., Yvelin C., Acar J. F. Pharmacokinetics of single intravenous and intramuscular doses of cefotetan in normal human volunteers. J Antimicrob Chemother. 1983 Jan;11 (Suppl):201–206. doi: 10.1093/jac/11.suppl_a.201. [DOI] [PubMed] [Google Scholar]
  6. Nakagawa K., Koyama M., Tachibana A., Komiya M., Kikuchi Y., Yano K. Pharmacokinetics of cefotetan (YM09330) in humans. Antimicrob Agents Chemother. 1982 Dec;22(6):935–941. doi: 10.1128/aac.22.6.935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ohkawa M., Hirano S., Tokunaga S., Motoi I., Shoda R., Ikeda A., Sugata T., Sawaki M., Shimamura M., Okasho A. Pharmacokinetics of cefotetan in normal subjects and patients with impaired renal function. Antimicrob Agents Chemother. 1983 Jan;23(1):31–35. doi: 10.1128/aac.23.1.31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Owen A. W., Manson J. M., Yates R. A., Adshead V. M., Houghton H. L., Tweedle D. E. The pharmacokinetics of cefotetan excretion in the unobstructed biliary tree. J Antimicrob Chemother. 1983 Jan;11 (Suppl):217–221. doi: 10.1093/jac/11.suppl_a.217. [DOI] [PubMed] [Google Scholar]
  9. Wright N., Wise R., Hegarty T. Cefotetan elimination in patients with varying degrees of renal dysfunction. J Antimicrob Chemother. 1983 Jan;11 (Suppl):213–216. doi: 10.1093/jac/11.suppl_a.213. [DOI] [PubMed] [Google Scholar]
  10. Yates R. A., Adam H. K., Donnelly R. J., Houghton H. L., Charlesworth E. A., Laws E. A. Pharmacokinetics and tolerance of single intravenous doses of cefotetan disodium in male Caucasian volunteers. J Antimicrob Chemother. 1983 Jan;11 (Suppl):185–191. doi: 10.1093/jac/11.suppl_a.185. [DOI] [PubMed] [Google Scholar]
  11. Yates R. A., Cockshott I. D., Houghton H. L., Wardleworth A., Adam H., Donnelly R. J. Pharmacokinetics and tolerance of single intramuscular doses of cefotetan in normal Caucasian volunteers. J Antimicrob Chemother. 1983 Jan;11 (Suppl):207–212. doi: 10.1093/jac/11.suppl_a.207. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES